BAY-43-9006 Bayer/Onyx

Curr Opin Investig Drugs. 2003 Jun;4(6):757-63.

Abstract

Bayer and Onyx are developing BAY-43-9006, an oral cytostatic Raf kinase inhibitor for the potential treatment of colorectal and breast cancers, hepatocellular carcinoma and non-small-cell lung cancer, in addition to acute myelogenous leukemia, myelodysplastic syndrome and other cancers. A US IND was filed in May 2000 and by February 2003 BAY-43-9006 was in phase II trials, with phase III trials expected to begin later in 2003.

Publication types

  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / metabolism
  • Antineoplastic Agents / therapeutic use*
  • Benzenesulfonates / chemistry
  • Benzenesulfonates / metabolism
  • Benzenesulfonates / therapeutic use*
  • Clinical Trials as Topic / statistics & numerical data
  • Drugs, Investigational* / chemistry
  • Drugs, Investigational* / metabolism
  • Drugs, Investigational* / therapeutic use
  • Humans
  • Neoplasms / drug therapy
  • Neoplasms / metabolism
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Pyridines / chemistry
  • Pyridines / metabolism
  • Pyridines / therapeutic use*
  • Sorafenib
  • Technology, Pharmaceutical / methods*

Substances

  • Antineoplastic Agents
  • Benzenesulfonates
  • Drugs, Investigational
  • Phenylurea Compounds
  • Pyridines
  • Niacinamide
  • Sorafenib